We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Advanced Accelerator (AAAP) Cancer Therapy Approved in EU
Read MoreHide Full Article
Advanced Accelerator Applications S.A. announced that the European Commission has authorized the marketing of its drug, Lutathera (lutetium oxodotreotide) for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NET) in adult patients. The approval allows the company to market the drug in Iceland, Norway and Liechtenstein along with 28 European Union countries.
The drug is under review in the United States. A decision is expected in January 2018.
Shares of the company were up almost 3.9% following the news on Friday. In fact, Advanced Accelerator Applications’ stock is up 152.7% so far this year, significantly outperforming the industry’s gain of 3.7% in that period.
The approval of the marketing authorization was based on data from a phase III study – NETTER-1 – which showed that Lutathera reduced progression free survival by 79% compared to octreotide LAR in patients with unresectable or metastatic, progressive, somatostatin receptor positive GEP-NET. Although the targeted overall survival (OS) data is yet to be reached, the current data showed 46% reduction in risk of death for Lutathera compared to octreotide.
The marketing authorization application also included efficacy and safety data from a Phase I/II study conducted by Erasmus Medical Center.
Per the European Society for Medical Oncology, GEP-NET occurs in 5.25 persons in a population of 100,000 every year.
The company markets SomaKit TOC in Europe and NETSPOT in the United States in GEP-NET patients for diagnostic purpose. It recorded revenues of €69.2 million in the first six months of 2017, an increase of 27% from the year-ago period.
Lutathera, a peptide receptor radionuclide therapy, is the company’s first drug approved as a therapeutic drug for GEP-NET.
However, Advanced Accelerator Applications recognizes three other radiopharmaceutical products already available in the market. These include Bayer AG’s (BAYRY - Free Report) Xofigo for prostate cancer, Zevalin from Spectrum Pharmaceuticals, Inc. and GlaxoSmithKline plc’s (GSK - Free Report) Bexxar for non-Hodgkin’s lymphoma.
Advanced Accelerator Applications S.A. Price and Consensus
It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
Image: Bigstock
Advanced Accelerator (AAAP) Cancer Therapy Approved in EU
Advanced Accelerator Applications S.A. announced that the European Commission has authorized the marketing of its drug, Lutathera (lutetium oxodotreotide) for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NET) in adult patients. The approval allows the company to market the drug in Iceland, Norway and Liechtenstein along with 28 European Union countries.
The drug is under review in the United States. A decision is expected in January 2018.
Shares of the company were up almost 3.9% following the news on Friday. In fact, Advanced Accelerator Applications’ stock is up 152.7% so far this year, significantly outperforming the industry’s gain of 3.7% in that period.
The approval of the marketing authorization was based on data from a phase III study – NETTER-1 – which showed that Lutathera reduced progression free survival by 79% compared to octreotide LAR in patients with unresectable or metastatic, progressive, somatostatin receptor positive GEP-NET. Although the targeted overall survival (OS) data is yet to be reached, the current data showed 46% reduction in risk of death for Lutathera compared to octreotide.
The marketing authorization application also included efficacy and safety data from a Phase I/II study conducted by Erasmus Medical Center.
Per the European Society for Medical Oncology, GEP-NET occurs in 5.25 persons in a population of 100,000 every year.
The company markets SomaKit TOC in Europe and NETSPOT in the United States in GEP-NET patients for diagnostic purpose. It recorded revenues of €69.2 million in the first six months of 2017, an increase of 27% from the year-ago period.
Lutathera, a peptide receptor radionuclide therapy, is the company’s first drug approved as a therapeutic drug for GEP-NET.
However, Advanced Accelerator Applications recognizes three other radiopharmaceutical products already available in the market. These include Bayer AG’s (BAYRY - Free Report) Xofigo for prostate cancer, Zevalin from Spectrum Pharmaceuticals, Inc. and GlaxoSmithKline plc’s (GSK - Free Report) Bexxar for non-Hodgkin’s lymphoma.
Advanced Accelerator Applications S.A. Price and Consensus
Advanced Accelerator Applications S.A. Price and Consensus | Advanced Accelerator Applications S.A. Quote
Advanced Accelerator Applications currently has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
See Them Free>>